Fesoterodine
- Atc Codes:G04BD11
- CAS Codes:286930-03-8
- PHARMGKB ID:286930-03-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Toviaz; Belgium: Toviaz; Bulgaria: Toviaz; Czech Republic: Toviaz; Denmark: Toviaz; Estonia: Toviaz; Finland: Toviaz; Germany: Toviaz; Greece: Toviaz; Hungary: Toviaz; Ireland: Toviaz; Italy: Toviaz; Latvia: Toviaz; Lithuania: Toviaz; Luxembourg: Toviaz; Malta: Toviaz; Netherlands: Toviaz; Poland: Toviaz; Portugal: Toviaz; Romania: Toviaz; Slovakia: Toviaz; Slovenia: Toviaz; Spain: Toviaz; Sweden: Toviaz; UK: Toviaz.
North America
USA: Toviaz.
Drug combinations
Chemistry
Fesoterodine Fumarate: C~30~H~41~NO~7~. Mw: 527.66. (1) Isobutyric acid 2-((R)-3-diisopropylammonium-1-phenylpropyl)-4-(hydroxymethyl) phenyl ester hydrogen fumarate; (2) 2-[(1R)-3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate fumarate; (3)(E)-but-2-enedioic acid; [2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate. CAS-286930-03-8.
Pharmacologic Category
Genitourinary Smooth Muscle Relaxants. Anticholinergic Agent. (ATC-Code: G04BD11).
Mechanism of action
Fesoterodine acts as a prodrug and is converted to an active metabolite, 5-hydroxymethyl tolterodine (5-HMT); 5-HMT is responsible for fesoterodine’s antimuscarinic activity and acts as a competitive antagonist of muscarinic receptors. Urinary bladder contractions are mediated by muscarinic receptors; fesoterodine inhibits the receptors in the bladder preventing symptoms of urgency and frequency.
Therapeutic use
Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Pregnancy and lactiation implications
Should be used during pregnancy only if potential benefit to mother outweighs potential risk to fetus. Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to fesoterodine or any component of the formulation. Urinary retention. Gastric retention. Uncontrolled narrow-angle glaucoma.
Warnings and precautions
Anticholinergics may cause drowsiness and/or blurred vision, which may impair physical or mental abilities. Heat prostration may occur in the presence of increased environmental temperature. Use with caution in bladder flow obstruction, decreased GI motility or GI obstructive disorders (i.e. pyloric stenosis). Use with caution in controlled (treated) narrow-angle glaucoma, myasthenia gravis and renal impairment.